Form D · Biotechnology
C2i Genomics, Inc.
New York, NY · CIK 0001813687
Offering snapshot reported Apr 14, 2021 · SEC filing
- Reported sold
- $50M Offering amount: $100M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 14, 2021 | Initial | $50,000,000 | No comparison | Not reported | SEC filing |
| Jun 8, 2020 | Initial | $12,000,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-395851
Source: Form D, filed Apr 14, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Omri Amirav Drori | Director |
| Eli Casdin | Director |
| Alex Parker | Director |
| Shaun Rodriguez | Director |
| Ezra Sofer | Director, Executive |
| Asaf Zviran | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
180 Varick Street
New York, NY, 10014
New York, NY, 10014